Drugs / Elvucitabine
Elvucitabine
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00312039 | Mar 2006 → Oct 2007 | HIV infectious disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 27 trials · 1 missed | ||||||
| Phase 2 | NCT00675844 | May 2008 → Mar 2010 | HIV infectious disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00405249 | Sep → Nov 2006 | HIV infectious disease | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 2 | NCT00380159 | Sep 2006 → Dec 2008 | HIV infectious disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00350272 | May 2006 → Aug 2007 | HIV infectious disease | Alexion Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 2 | NCT00040144 | Jul 2002 → May 2003 | chronic hepatitis B virus infection | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00034359 | Feb 2002 → Jan 2003 | chronic hepatitis B virus infection | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00040157 | ? → May 2003 | HIV infectious disease | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00037622 | ? → May 2003 | chronic hepatitis B virus infection | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elvucitabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00312039 ↗ |
| Known as | ACH-126, 443 | “Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.” NCT00040157 ↗ |
| Known as | ACH126, 433 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00040144 ↗ |
| Known as | beta-L-Fd4C | “The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase...” NCT00037622 ↗1“ACH126-443 (Beta-L-Fd4C)” NCT00040157 ↗ |
| Known as | Elvucitabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL38700 ↗ |
| Known as | L-fd4c | ChEMBL registry synonym — accepted as the source's own label CHEMBL38700 ↗ |
| Modality | Small molecule | “Elvucitabine, a novel nucleoside analog” NCT00350272 ↗ |
| Route | Oral | “12 Weeks Oral Treatment With ACH-126,443” NCT00034359 ↗ |